Numazu, Shizuoka, Japan - November 1, 2011 - CanBas Co., Ltd. announces the initiation of treatment of the last patient in the company’s 63-patient randomized multi-national Phase II trial to evaluate CBP501 as first-line therapy for malignant pleural mesothelioma (MPM).
Dr. Takumi Kawabe, CEO of CanBas, said, “We have now completed enrollment of both of our Phase II trials with our lead drug, CBP501, for first-line treatment of MPM and first-line treatment of 192 patients with non-small cell lung cancer. We are pleased to have achieved these developmental milestones with a new drug for these patients, who desperately need more effective therapies. We look forward to reporting the results of these trials and advancing CBP501 into Phase III studies.”
About CBP501
CanBas‘ lead product, CBP501 is a novel synthetic peptide that enhances the efficacy of cisplatin when administered in combination. CBP501 acts on multiple pathways related to the cell cycle and DNA damage repair. Mechanisms of action include G2 checkpoint abrogation and modulation of calmodulin activity, which leads to increased cytotoxicity resulting from accumulation of platinum in tumor cells and suppression of DNA damage repair. CBP501 was discovered using CanBas’ proprietary phenotypic screen for G2 abrogation activity. CanBas is currently conducting randomized Phase II clinical trials in the US and other countries using CBP501 in combination therapy for first-line treatment of patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Phase I studies have demonstrated promising combination efficacy in ovarian cancer. CBP501 has also demonstrated the ability to resensitize tumor cells that have become resistant / refractory to cisplatin.
About CanBas
CanBas is a publicly listed (Tokyo Stock Exchange: M-4575) clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology drugs targeting the cell cycle. Using its proprietary phenotypic screening platform, CanBas has identified a pipeline of novel oncology drug candidates, including its lead product, CBP501. CanBas’ pipeline also includes CBS9106, a preclinical stage, synthetic small molecule that demonstrates cancer cell-specific cytotoxicity, both alone and in synergy with specific DNA-damaging treatments, acting through inhibition and destabilization of CRM1.
Source: CanBas Co., Ltd.
Contacts:
Takumi Kawabe, CEO
CanBas Co., Ltd.
CBP501@canbas.co.jp
Vivian Lee
Aqua Partners LLC
vlee@aquapartners.net
Website: http://www.canbas.co.jp/eng/
